Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Johnson & JohnsonXSWX:JNJ -4.03%24 3-Year EBITDA Growth Rate is 19.20% as of Jun. 2026, which is 106% above its 10-year median of 9.30. GuruFocus rates XSWX:JNJ with a GF Score™ of 24/100 and a GF Value™ of CHF161.26 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 812 Drug Manufacturers companies, Johnson & Johnson ranks better than 67.36% on this metric.
During the past 12 months, Johnson & Johnson's average EBITDA Per Share Growth Rate was -5.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 19.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 9.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 4.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Johnson & Johnson was 19.30% per year. The lowest was -6.60% per year. And the median was 9.30% per year.
Johnson & Johnson (XSWX:JNJ) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Johnson & Johnson 3-Year EBITDA Growth Rate Related Terms
XSWX:JNJ vs ABBV, MRK, LLY: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Johnson & Johnson's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Johnson & Johnson 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Johnson & Johnson's 3-Year EBITDA Growth Rate falls into.
Johnson & Johnson 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 19.20% mean?
Johnson & Johnson (XSWX:JNJ) has a 3-Year EBITDA Growth Rate of 19.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Johnson & Johnson and its competitors. This is 106% above median its historical median of 9.30. According to the industry distribution chart, Johnson & Johnson ranks #265 out of 812 companies in the Drug Manufacturers industry, placing it in the top 32.6%.
Is Johnson & Johnson's 3-Year EBITDA Growth Rate too high?
Johnson & Johnson's current 3-Year EBITDA Growth Rate of 19.20% is 106% above median its 10-year median of 9.30. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.75. Johnson & Johnson's value of 19.20% is 119.4% above this industry median. Based on the distribution chart, Johnson & Johnson ranks #265 out of 812 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Johnson & Johnson has a GF Score™ of 24/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Johnson & Johnson's 3-Year EBITDA Growth Rate compare to ABBV and MRK?
According to the Drug Manufacturers industry distribution chart, Johnson & Johnson ranks #265 out of 812 companies for 3-Year EBITDA Growth Rate. This puts Johnson & Johnson in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.75. Johnson & Johnson's value of 19.20% is 119.4% above this benchmark. While the company's 10-year median is 9.30 vs. the industry median of 8.75, Johnson & Johnson has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.75, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Johnson & Johnson's current 3-Year EBITDA Growth Rate of 19.20% is 119.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Johnson & Johnson and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Johnson & Johnson's current 3-Year EBITDA Growth Rate is 19.20%, which is 106% above median its own 10-year median of 9.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson & Johnson stock overvalued right now?
Based on GuruFocus' analysis, Johnson & Johnson (XSWX:JNJ) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF161.26, compared to a current price of CHF205.05 — trading 27.2% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 19.20%, which is 106% above median its 10-year median of 9.30 and 119.4% above the Drug Manufacturers industry median of 8.75. Johnson & Johnson's overall GF Score™ is 24/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Johnson & Johnson (XSWX:JNJ), the current 3-Year EBITDA Growth Rate is 19.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Johnson & Johnson (XSWX:JNJ) Overvalued in 2026?
Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued.
The current stock price of CHF205.05 is trading 27.2% above its estimated GF Value™ of CHF161.26.
GuruFocus considers Johnson & Johnson to be Modestly Overvalued.
Key valuation signals for XSWX:JNJ:
3-Year EBITDA Growth Rate: 19.20% (106% above median its 10-year median of 9.30)
GF Value™: CHF161.26 vs. price of CHF205.05 (27.2% above fair value)
Industry Position: 119.4% above the Drug Manufacturers median (#265 of 812)
No single metric tells the full story. See the XSWX:JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
24GF Score
Get the complete analysis for XSWX:JNJ
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:JNJ has been successfully added to your 
